Littérature scientifique sur le sujet « Endocryne tumour »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Endocryne tumour ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Endocryne tumour"
Lenzen, S., G. Klöppel, S. Zielmann et U. Panten. « Secretory, enzymatic, and morphological characterization of rat pancreatic endocrine tumours induced by streptozotocin and nicotinamide ». Acta Endocrinologica 109, no 3 (juillet 1985) : 361–68. http://dx.doi.org/10.1530/acta.0.1090361.
Texte intégralAsa, Sylvia L., William Singer, Kalman Kovacs, Eva Horvath, David Murray, Nicholas Colapinto et Michael O. Thorner. « Pancreatic endocrine tumour producing growth hormone-releasing hormone associated with multiple endocrine neoplasia type I syndrome ». Acta Endocrinologica 115, no 3 (juillet 1987) : 331–37. http://dx.doi.org/10.1530/acta.0.1150331.
Texte intégralTurner, HE, Z. Nagy, KC Gatter, MM Esiri, AL Harris et JA Wass. « Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome ». Journal of Endocrinology 165, no 2 (1 mai 2000) : 475–81. http://dx.doi.org/10.1677/joe.0.1650475.
Texte intégralSarkadi, Balázs, Vince Kornél Grolmusz, Henriett Butz, Annamária Kövesdi, István Likó, Gábor Nyirő, Péter Igaz et Attila Patócs. « Molekuláris genetikai vizsgálatok az örökletes endokrinológiai tumor szindrómák klinikai diagnosztikájában ». Orvosi Hetilap 159, no 7 (février 2018) : 285–92. http://dx.doi.org/10.1556/650.2018.31036.
Texte intégralArnold, R., R. Benning, C. Neuhaus, M. Rolwage et M. E. Trautmann. « Gastroenteropancreatic Endocrine Tumours : Effect of Sandostatin® on Tumour Growth ». Digestion 54, no 1 (1993) : 72–75. http://dx.doi.org/10.1159/000201081.
Texte intégralIgaz, Péter. « Genetics of neuroendocrine tumours, hereditary tumour syndromes ». Orvosi Hetilap 154, no 39 (septembre 2013) : 1541–48. http://dx.doi.org/10.1556/oh.2013.29706.
Texte intégralMarques, Pedro, Ashley B. Grossman et Márta Korbonits. « The tumour microenvironment of pituitary neuroendocrine tumours ». Frontiers in Neuroendocrinology 58 (juillet 2020) : 100852. http://dx.doi.org/10.1016/j.yfrne.2020.100852.
Texte intégralDimitriadis, Georgios K., Anna Angelousi, Martin O. Weickert, Harpal S. Randeva, Gregory Kaltsas et Ashley Grossman. « Paraneoplastic endocrine syndromes ». Endocrine-Related Cancer 24, no 6 (juin 2017) : R173—R190. http://dx.doi.org/10.1530/erc-17-0036.
Texte intégralde Sá, Sandra Valéria, Maria Lúcia Corrêa-Giannella, Márcio Carlos Machado, Jean Jorge S. de Souza, Maria Adelaide Albergaria Pereira, Rosely Antunes Patzina, Sheila Aparecida Coelho Siqueira, Marcel Cerqueira César Machado et Daniel Giannella-Neto. « Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas ». Endocrine-Related Cancer 13, no 1 (mars 2006) : 69–78. http://dx.doi.org/10.1677/erc.1.00962.
Texte intégralMadeira, I., B. Terris, M. Voss, A. Denys, A. Sauvanet, J.-F. Flejou, V. Vilgrain, J. Belghiti, P. Bernades et P. Ruszniewski. « Prognostic factors in patients with endocrine tumours of the duodenopancreatic area ». Gut 43, no 3 (1 septembre 1998) : 422–27. http://dx.doi.org/10.1136/gut.43.3.422.
Texte intégralThèses sur le sujet "Endocryne tumour"
BRAGANTINI, Emma. « Prognostic significance of cytokeratin 19 in pancreatic endocrine tumours ». Doctoral thesis, Università degli Studi di Verona, 2009. http://hdl.handle.net/11562/337410.
Texte intégralAim: Pancreatic endocrine tumours are rare neoplasm, whose behaviour is difficult to predict. Recent 2004 WHO classification gives clear criteria to define prognosis of PET, but despite these criteria some tumours show a more aggressive course. Recent studies lighted the role of some immunohistochemical markers as CK19, CD99, P27 as prognostic marker in pancreatic endocrine. The aim of this study was to evaluate the prognostic value of CK19 expression in PETs. Methods and results: 149 PETs and 35 mached metastases were studied using tissue array technology and evaluating immunohistochemical expression of CK19. The presence of CK 19 was detected in a total of 100/149 primitive tumours (67.1%) and 26/35 (74.2%) metastases both in lymph node and in other sites. The difference between the prevalence of CK 19 in metastasis and primitive tumours was not significant. There was a strong correlation between presence of CK 19 in the primitive and its matched metastasis (Fisher's test; P = 0.0012). The results were statistically compared with follow up data, showing a significant correlation with with tumour dimension, lymph node status, presence of metastasis, 5 years survival, and with the subgroups of WHO 2004 classification that have a worse prognosis (WDEC and PDEC). When the WHO parameter was added to the model, ck19 was no longer significantly associated with survival. Furthermore, ck19 expression was not significantly associated with survival when evaluated in single WHO subgroups. Conclusions: We conclude that ck19 can be used as a malignancy marker and index but they are not an independent prognostic markers
Restany, Alain. « Les tumeurs endocrines du pancréas à sécrétions multiples : considérations pathogéniques et thérapeutiques ». Montpellier 1, 1988. http://www.theses.fr/1988MON11263.
Texte intégralBonnavion, Rémy. « Study of the effects of Men1 disruption in mouse pancreatic endocrine progenitors during development and adult life ». Thesis, Lyon 1, 2013. http://www.theses.fr/2013LYO10144/document.
Texte intégralMultiple Endocrine Neoplasia Type I syndrome (MEN1) is a rare hereditary tumoral disease characterized by the apparition of tumors in multiple endocrine organs including the endocrine pancreas. MEN1 patients generally carry a germinal mutation on one allele of the predisposing gene to the disease, the tumor suppressor MEN1. Pancreatic endocrine tumors are rare, slowly evolving and often present with metastasis at diagnosis. These tumors constitute a heterogeneous group defined by their hormonal secretions. Evolution and development of these tumors is far from being understood. The cell of origin of the different pancreatic endocrine tumor types is enigmatic, notably for tumors secreting non-pancreatic hormones such as gastrinomas. My thesis project was structured toward the characterization of a new murine model allowing the specific disruption of the Men1 gene in Ngn3+ pancreatic endocrine progenitors, the PancEndoMen1 KO model. The combined study of this new model and previous model generated in the team, allowed us to demonstrate that pancreatic gastrinomas related to Men1 inactivation, originate from the endogenous pancreatic endocrine cells. In parallel, our results demonstrated that the mutant mice having Men1-deficient Ngn3+-progenitors resulted in differential cell proliferation alterations in different pancreatic endocrine cells. Importantly, Men1-disruption in either pancreatic endocrine or pan-pancreatic progenitors displayed tumors with impaired differentiation features. Thus, this thesis works allowed to better characterize pancreatic endocrine tumors histogenesis by addressing the role of pancreatic endocrine progenitors targeted Men1 disruption during development in tumorigenesis
Kaboré, Moussa. « Contribution à l'étude des tumeurs neuro-endocrines : à propos d'un cas de "tumeur carcinoi͏̈de" de l'ovaire, avec dissémination péritonéale ». Bordeaux 2, 1989. http://www.theses.fr/1989BOR25283.
Texte intégralL', Hopital François. « Tumeur endocrine pancréatique secrétant calcitonine et glucagon ». Clermont-Ferrand 1, 1987. http://www.theses.fr/1987CLF11048.
Texte intégralCuny, Thomas. « New regulatory mechanisms in the growth of endocrine tumors : digestive neuroendocrine tumors, pitiutary adenomas ». Thesis, Aix-Marseille, 2016. http://www.theses.fr/2016AIXM5061.
Texte intégralAlthough rare, endocrine tumors developed in Humans remain problematic, such as a better understanding of their regulatory mechanisms of growth represent a step forward to identify new therapeutical targets.In the first part of this thesis, we investigated the impact of the tumor microenvironment (TME), as defined by the factors surrounding the tumor primitive niche, on the growth of human digestive endocrine tumors. We, here, showed the occurrence of a reciprocal proliferation between human fibroblasts, a key cell within the TME, and human pancreatic neuroendocrine tumor cell lines, suggesting that human fibroblasts may constitue a new therapeutical target of interest in the TME of digestive endocrine tumors. In a second part, we showed that pegvisomant (PEG), a growth hormone receptor antagonist currently used in patients with GH-secreting pituitary adenoma, did not impact in vitro the proliferation rate of GH-secreting adenoma cells and therefore is suitable in patients with a persisting GH-secreting pituitary adenoma residue after surgery
Villaume, Karine. « Mécanismes de l'angiogenèse associée aux tumeurs endocrine digestives : rôle du VEGF ». Thesis, Lyon 1, 2009. http://www.theses.fr/2009LYO10189/document.
Texte intégralDigestive endocrine tumors are hypervascular tumors, likely to be associated with an active angiogenic process. The mechanisms of tumor angiogenesis in digestive endocrine tumors are complex. Two processes seem to coexist: well differentiated tumors are able to recapitulate the pro-angiogenic capacities of normal endocrine cells whereas less differentiated and more aggressive tumors are associated with a non specific angiogenic process, in response to hypoxia. In both processes, VEGF is likely to play an important role, since it is constitutively expressed by normal peptide-secreting endocrine cells, as part of their specific differentiation program. Our aim was to evaluate the mechanisms of regulation of VEGF synthesis and secretion by neoplastic digestive endocrine tumors and to analyze its role in tumor progression, through an in vitro and in vivo experimental approach. We were able to demonstrate that: (a) the regulation of VEGF synthesis and secretion is complex and involves several pathways (PI3K/Akt/mTOR and p38/MAPK), with different roles according to the cell studied; (b) there is a dissociation between VEGF expression and angiogenic capacities, on one hand, and invasive and metastatic properties, on the other hand; (c) the inhibition of angiogenesis may contribute to the anti-tumoral effect of several drugs of therapeutic interest in digestive endocrine tumors
Hessman, Ola. « Genetic studies of endocrine abdominal tumors ». Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2001. http://publications.uu.se/theses/91-554-5026-1/.
Texte intégralLarsson, Gunnel. « Quality of Life in Patients with Endocrine Gastrointestinal Tumours ». Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2001. http://publications.uu.se/theses/91-554-4916-6/.
Texte intégralTsolakis, Apostolos V. « Characterization of Endocrine Cells and Tumours in the Stomach ». Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-8804.
Texte intégralLivres sur le sujet "Endocryne tumour"
Donal, O'Shea, et Bloom Stephen Robert, dir. Gastrointestinal endocrine tumours. London : Baillière Tindall, 1996.
Trouver le texte intégralH, Clark Orlo, et American Cancer Society, dir. Endocrine tumors. Hamilton, Ont : BC Decker, 2003.
Trouver le texte intégral1936-, Mazzaferri Ernest L., et Samaan Naguib A. 1925-, dir. Endocrine tumors. Boston : Blackwell Scientific Publications, 1993.
Trouver le texte intégralChapman, Catherine Eluned. Radioimmunodetection of endocrine tumours. Birmingham : University of Birmingham, 1987.
Trouver le texte intégralSocinski, Mark A. Endocrine tumours and malignancies. London : Mosby-Wolfe, 1996.
Trouver le texte intégralAndrew, Arnold, dir. Endocrine neoplasms. Boston : Kluwer Academic Publishers, 1997.
Trouver le texte intégralM, Polak Julia, et Bloom Stephen Robert, dir. Endocrine tumours : The pathobiology ofregulatory peptide-producing tumours. Edinburgh : Churchill Livingstone, 1985.
Trouver le texte intégralSolcia, Enrico, Günter Klöppel et Leslie H. Sobin. Histological Typing of Endocrine Tumours. Berlin, Heidelberg : Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-59655-1.
Texte intégralM, Polak Julia, et Bloom Stephen Robert, dir. Endocrine tumours : The pathobiology of regulatory peptide-producing tumours. Edinburgh : Churchill Livingstone, 1985.
Trouver le texte intégralSurgical pathology of endocrine and neuroendocrine tumors. New York, NY : Humana Press, 2009.
Trouver le texte intégralChapitres de livres sur le sujet "Endocryne tumour"
Asa, Sylvia L. « Corticotroph Tumor ». Dans Endocrine Pathology, 144–48. Cham : Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-62345-6_5034.
Texte intégralAsa, Sylvia L. « Lactotroph Tumor ». Dans Endocrine Pathology, 465–67. Cham : Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-62345-6_5037.
Texte intégralAsa, Sylvia L. « Mammosomatotroph Tumor ». Dans Endocrine Pathology, 481–83. Cham : Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-62345-6_5038.
Texte intégralAsa, Sylvia L. « Somatotroph Tumor ». Dans Endocrine Pathology, 746–49. Cham : Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-62345-6_5053.
Texte intégralAsa, Sylvia L. « Thyrotroph Tumor ». Dans Endocrine Pathology, 805–7. Cham : Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-62345-6_5055.
Texte intégralAsa, Sylvia L. « Gonadotroph Tumor ». Dans Endocrine Pathology, 336–38. Cham : Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-62345-6_5036.
Texte intégralKlopfleisch, Robert. « Endocrine Tumors ». Dans Veterinary Oncology, 217–44. Cham : Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-41124-8_12.
Texte intégralKrausz, Yodphat. « Endocrine Tumors ». Dans Hybrid PET/CT and SPECT/CT Imaging, 475–511. New York, NY : Springer New York, 2009. http://dx.doi.org/10.1007/978-0-387-92820-3_13.
Texte intégralKruseman, A. C. Nieuwenhuijzen. « Endocrine Tumors. » Dans Application of Monoclonal Antibodies in Tumor Pathology, 255–63. Dordrecht : Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3299-9_14.
Texte intégralBrandt, Mary. « Endocrine Tumors ». Dans Pearls and Tricks in Pediatric Surgery, 443–48. Cham : Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-51067-1_63.
Texte intégralActes de conférences sur le sujet "Endocryne tumour"
Chopra, Seema. « Sclerosing sex cord stromal tumour of the ovary : A rare variant of ovarian neoplasms in childhood and adolescence ». Dans 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685321.
Texte intégralQurbanova R.Sh., Asadova Sh.Sh., Vahabova Sh.B., Qurbanova R. Sh ,. Asadova Sh Sh ,. Vahabova Sh B. « CLİNİCAL AND MORPHOLOGİCAL PATTERNS OF ENDOCCRİNE-CELL CARSİNOMA OF UTERİ ». Dans THE FIRST INTERNATIONAL SCIENTIFIC – PRACTICAL VIRTUAL CONFERENCE IN MODERN & SOCIAL SCIENCES : NEW DIMENSIONS, APPROACHES AND CHALLENGES. IRETC, 2022. http://dx.doi.org/10.36962/mssndac-01-11.
Texte intégralLarionov, A., D. Faratian, H. Caldwell, A. Sims, A. Fawkes, L. Murphy, L. Renshaw, J. Dixon et J. Dixon. « miRNA Profiling of Endocrine-Resistant Breast Tumours. » Dans Abstracts : Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009 ; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-5130.
Texte intégralLarionov, A., D. Faratian, H. Caldwell, A. Sims, A. Fawkes, L. Murphy, L. Renshaw, J. Dixon et J. Dixon. « Gene Expression Profiles of Endocrine Resistant Breast Tumours. » Dans Abstracts : Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009 ; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-5132.
Texte intégralLarionov, A., D. Faratian, H. Caldwell, A. Sims, A. Fawkes, L. Murphy, L. Renshaw, J. Dixon et J. Dixon. « Genes Regulated by miRNA in Endocrine-Resistant Breast Tumours. » Dans Abstracts : Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009 ; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-5149.
Texte intégralHerold, Kevan. « Abstract IA09 : Checkpoint inhibitor-induced autoimmune diabetes and endocrine syndromes ». Dans Abstracts : AACR Special Conference on Tumor Immunology and Immunotherapy ; November 17-20, 2019 ; Boston, MA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/2326-6074.tumimm19-ia09.
Texte intégralBianchini, G., L. Pusztai, T. Iwamoto, CM Kelly, M. Zambetti, A. Fasolo, G. Del Conte, L. Santarpia, WF Symmans et L. Gianni. « S1-7 : Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome. » Dans Abstracts : Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011 ; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-s1-7.
Texte intégralPaulinelli, Régis Resende, Luiz Fernando Jubé Ribeiro, Thauana Dias Santos, Elisana Maria Santos Caires, Marilha Gabriella Martins Pontes et Bruna Morais Faria. « ONCOPLASTIC MAMMAPLASTY WITH DISGUISED GEOMETRIC COMPENSATION ». Dans Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2020.
Texte intégralFreitas, Paola Ferreira, Juliana Costa Souza, Andre Mattar, Jorge Yoshinori Shida et Luiz Henrique Gebrim. « NEOAJUVANT ENDOCRINE THERAPY IN BREAST CANCER : THE FIRST RESULTS OF 59 PATIENTS ». Dans Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1086.
Texte intégralGarcia, Cathy, Jaffarguriqbal Singh, Lauren Lawres, Sherry Agabiti, Daniel B. Burkhardt, Alexander Tong, Rebecca Cardone, Richard G. Kibbey, Smita Krishnaswamy et Mandar D. Muzumdar. « Abstract LT013 : Endocrine-exocrine signaling is a driver of obesity-associated pancreatic ductal adenocarcinoma ». Dans Abstracts : AACR Virtual Special Conference : The Evolving Tumor Microenvironment in Cancer Progression : Mechanisms and Emerging Therapeutic Opportunities ; in association with the Tumor Microenvironment (TME) Working Group ; January 11-12, 2021. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.tme21-lt013.
Texte intégralRapports d'organisations sur le sujet "Endocryne tumour"
Klapperich, Catherine, et Jennifer Rosen. Barriers to Therapy : A Novel 3-D Model to Study the Effect of Tumor Interstitial Pressure on Endocrine-Resistant Breast Cancer. Fort Belvoir, VA : Defense Technical Information Center, juillet 2007. http://dx.doi.org/10.21236/ada475124.
Texte intégralMeidan, Rina, et Joy Pate. Roles of Endothelin 1 and Tumor Necrosis Factor-A in Determining Responsiveness of the Bovine Corpus Luteum to Prostaglandin F2a. United States Department of Agriculture, janvier 2004. http://dx.doi.org/10.32747/2004.7695854.bard.
Texte intégral